References
- Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews, 113, 179–189. https://doi.org/https://doi.org/10.1016/j.neubiorev.2020.03.017
- Åkesdotter, C., Kenttä, G., Eloranta, S., & Franck, J. (2020). The prevalence of mental health problems in elite athletes. Journal of Science and Medicine in Sport, 23(4), 329–335. https://doi.org/https://doi.org/10.1016/j.jsams.2019.10.022
- Arnold, R., & Fletcher, D. (2012). A research synthesis and taxonomic classification of the organizational stressors encountered by sport performers. Journal of Sport & Exercise Psychology, 34(3), 397–429. https://doi.org/https://doi.org/10.1123/jsep.34.3.397
- Baranoff, J., Hanrahan, S. J., & Connor, J. P. (2015). The roles of acceptance and catastrophizing in rehabilitation following anterior cruciate ligament reconstruction. Journal of Science and Medicine in Sport, 18(3), 250–254. https://doi.org/https://doi.org/10.1016/j.jsams.2014.04.002
- Baum, A. L. (2005). Suicide in athletes: A review and commentary. Clinics in Sports Medicine, 24(4), 853–869. https://doi.org/https://doi.org/10.1016/j.csm.2005.06.006
- Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017). Patient experiences of psilocybin-assisted psychotherapy: An interpretative phenomenological analysis. Journal of Humanistic Psychology, 57(4), 354–388. https://doi.org/https://doi.org/10.1177/0022167817706884
- Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299. https://doi.org/https://doi.org/10.1177/0269881114565144
- Bonomo, Y., Norman, A., Biondo, S., Bruno, R., Daglish, M., Dawe, S., Egerton-Warburton, D., Karro, J., Kim, C., Lenton, S., Lubman, D. I., Pastor, A., Rundle, J., Ryan, J., Gordon, P., Sharry, P., Nutt, D., & Castle, D. (2019). The Australian drug harms ranking study. Journal of Psychopharmacology, 33(7), 759–768. https://doi.org/https://doi.org/10.1177/0269881119841569
- Brewer, B. W., Cornelius, A. E., Stephan, Y., & Van Raalte, J. (2010). Self-protective changes in athletic identity following anterior cruciate ligament reconstruction. Psychology of Sport and Exercise, 11(1), 1–5. https://doi.org/https://doi.org/10.1016/j.psychsport.2009.09.005
- Brewer, B. W., & Petitpas, A. J. (2017). Athletic identity foreclosure. Current Opinion in Psychology, 16, 118–122. https://doi.org/https://doi.org/10.1016/j.copsyc.2017.05.004
- Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. https://doi.org/https://doi.org/10.1177/0269881116662634
- Carhart-Harris, R. L. (2018). The entropic brain – Revisited. Neuropharmacology, 142, 167–178. https://doi.org/https://doi.org/10.1016/j.neuropharm.2018.03.010
- Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/https://doi.org/10.1007/s00213-017-4771-x
- Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/https://doi.org/10.1016/S2215-0366(16)30065-7
- Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 42(11), 2105–2113. https://doi.org/https://doi.org/10.1038/npp.2017.84
- Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014). The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. Frontiers in Human Neuroscience, 8, 20. https://doi.org/https://doi.org/10.3389/fnhum.2014.00020
- Carhart-Harris, R. L., Leech, R., Williams, T. M., Erritzoe, D., Abbasi, N., Bargiotas, T., Hobden, P., Sharp, D. J., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. British Journal of Psychiatry, 200(3), 238–244. https://doi.org/https://doi.org/10.1192/bjp.bp.111.103309
- Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018). Psychedelics and the essential importance of context. Journal of Psychopharmacology, 32(7), 725–731. https://doi.org/https://doi.org/10.1177/0269881118754710
- Cavnar, C. (2014). The effects of ayahuasca ritual participation on gay and lesbian identity. Journal of Psychoactive Drugs, 46(3), 252–260. https://doi.org/https://doi.org/10.1080/02791072.2014.920117
- Chang, C., Putukian, M., Aerni, G., Diamond, A., Hong, G., Ingram, Y., Reardon, C. L., & Wolanin, A. (2020). Mental health issues and psychological factors in athletes: detection, management, effect on performance and prevention: American Medical Society for Sports Medicine Position Statement-Executive Summary. British Journal of Sports Medicine, 54(4), 216–220. https://doi.org/https://doi.org/10.1136/bjsports-2019-101583
- Cohen, S. (1960). Lysergic acid diethylamide: side effects and complications. The Journal of Nervous and Mental Disease, 130(1), 30–40. https://doi.org/https://doi.org/10.1097/00005053-196001000-00005
- Cohen, S. (1967). The beyond within: The LSD story. Atheneum.
- Currie, A., & Johnston, A. (2016). Psychiatric disorders: The psychiatrist’s contribution to sport. International Review of Psychiatry, 28(6), 587–594. https://doi.org/https://doi.org/10.1080/09540261.2016.1197188
- Doherty, S., Hannigan, B., & Campbell, M. J. (2016). The experience of depression during the careers of elite male Athletes. Frontiers in Psychology, 7, 1069. https://doi.org/https://doi.org/10.3389/fpsyg.2016.01069
- Dolder, P. C., Schmid, Y., Müller, F., Borgwardt, S., & Liechti, M. E. (2016). LSD acutely impairs fear recognition and enhances emotional empathy and sociality. Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology, 41(11), 2638–2646. https://doi.org/https://doi.org/10.1038/npp.2016.82
- Donohue, B., Gavrilova, Y., Galante, M., Gavrilova, E., Loughran, T., Scott, J., Chow, G., Plant, C. P., & Allen, D. N. (2018). Controlled Evaluation of an Optimization Approach to Mental Health and Sport Performance. Journal of Clinical Sport Psychology, 12(2), 234–267. https://doi.org/https://doi.org/10.1123/jcsp.2017-0054
- Fadiman, J. (2011). The psychedelic explorer’s guide: Safe, therapeutic, and sacred journeys. Simon and Schuster.
- Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology, 33(9), 1088–1101. https://doi.org/https://doi.org/10.1177/0269881119845793
- Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014). Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. The Journal of Nervous and Mental Disease, 202(7), 513–520. https://doi.org/https://doi.org/10.1097/nmd.0000000000000113
- Gouttebarge, V., Castaldelli-Maia, J. M., Gorczynski, P., Hainline, B., Hitchcock, M. E., Kerkhoffs, G. M., Rice, S. M., & Reardon, C. L. (2019). Occurrence of mental health symptoms and disorders in current and former elite athletes: A systematic review and meta-analysis. British Journal of Sports Medicine, 53(11), 700–706. https://doi.org/https://doi.org/10.1136/bjsports-2019-100671
- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/https://doi.org/10.1177/0269881116675513
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., & Klinedinst, M. A. (2018). Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. Journal of Psychopharmacology, 32(1), 49–69. https://doi.org/https://doi.org/10.1177/0269881117731279
- Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187(3), 268–283. https://doi.org/https://doi.org/10.1007/s00213-006-0457-5
- Grinspoon, L., & Bakalar, J. B. (1979). Psychedelic drugs reconsidered. Basic Books.
- Grinspoon, L., & Bakalar, J. B. (1981). The psychedelic drug therapies. Current Psychiatric Therapies, 20, 275–283.
- Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry, 68(1), 71–78. https://doi.org/https://doi.org/10.1001/archgenpsychiatry.2010.116
- Gulliver, A., Griffiths, K. M., & Christensen, H. (2012). Barriers and facilitators to mental health help-seeking for young elite athletes: A qualitative study. BMC Psychiatry, 12(1), 157. https://doi.org/https://doi.org/10.1186/1471-244x-12-157
- Hofmann, A., & Ott, J. (1980). LSD, my problem childm, (Vol. 5). McGraw-Hill.
- Johansen, P. O., & Krebs, T. S. (2015). Psychedelics not linked to mental health problems or suicidal behavior: A population study. Journal of Psychopharmacology, 29(3), 270–279. https://doi.org/https://doi.org/10.1177/0269881114568039
- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992. https://doi.org/https://doi.org/10.1177/0269881114548296
- Johnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018). The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. Neuropharmacology, 142, 143–166. https://doi.org/https://doi.org/10.1016/j.neuropharm.2018.05.012
- Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/https://doi.org/10.1177/0269881108093587
- Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018). Positive psychology in the investigation of psychedelics and entactogens: A critical review. Neuropharmacology, 142, 179–199. https://doi.org/https://doi.org/10.1016/j.neuropharm.2018.06.034
- Keyes, C. L. (2002). The mental health continuum: From languishing to flourishing in life. Journal of Health and Social Behavior, 43(2), 207–222. https://doi.org/https://doi.org/10.2307/3090197
- Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and mental health: A population study. PLoS One, 8(8), e63972. https://doi.org/https://doi.org/10.1371/journal.pone.0063972
- Lerner, A. G., Gelkopf, M., Skladman, I., Oyffe, I., Finkel, B., Sigal, M., & Weizman, A. (2002). Flashback and hallucinogen persisting perception disorder: Clinical aspects and pharmacological treatment approach. The Israel Journal of Psychiatry and Related Sciences, 39(2), 92–99.
- Luoma, J. B., Sabucedo, P., Eriksson, J., Gates, N., & Pilecki, B. C. (2019). Toward a contextual psychedelic-assisted therapy: Perspectives from Acceptance and Commitment Therapy and contextual behavioral science. Journal of Contextual Behavioral Science, 14, 136–145. https://doi.org/https://doi.org/10.1016/j.jcbs.2019.10.003
- MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology, 25(11), 1453–1461. https://doi.org/https://doi.org/10.1177/0269881111420188
- Mannes, Z. L., Waxenberg, L. B., Cottler, L. B., Perlstein, W. M., Burrell Ii, L. E., Ferguson, E. G., Edwards, M. E., & Ennis, N. (2019). Prevalence and correlates of psychological distress among retired elite athletes: A systematic review. International Review of Sport and Exercise Psychology, 12(1), 265–230. https://doi.org/https://doi.org/10.1080/1750984X.2018.1469162
- Mazzoni, I., Barroso, O., & Rabin, O. (2017). Anti-doping Challenges with Novel Psychoactive Substances in Sport. In O. Corazza & A. Roman-Urrestarazu (Eds.), Novel Psychoactive Substances: Policy, Economics and Drug Regulation (pp. 43–56). Springer International Publishing.
- McDuff, D., Stull, T., Castaldelli-Maia, J. M., Hitchcock, M. E., Hainline, B., & Reardon, C. L. (2019). Recreational and ergogenic substance use and substance use disorders in elite athletes: a narrative review. British Journal of Sports Medicine, 53(12), 754–760. https://doi.org/https://doi.org/10.1136/bjsports-2019-100669
- Meikle, S. E., Liknaitzky, P., Rossell, S. L., Ross, M., Strauss, N., Thomas, N., Murray, G., Williams, M., & Castle, D. J. (2020). Psilocybin-assisted therapy for depression: How do we advance the field? The Australian and New Zealand Journal of Psychiatry, 54(3), 225–231. https://doi.org/https://doi.org/10.1177/0004867419888575
- Moreland, J. J., Coxe, K. A., & Yang, J. (2018). Collegiate athletes’ mental health services utilization: A systematic review of conceptualizations, operationalizations, facilitators, and barriers. Journal of Sport and Health Science, 7(1), 58–69. https://doi.org/https://doi.org/10.1016/j.jshs.2017.04.009
- Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 67(11), 1735–1740. https://doi.org/https://doi.org/10.4088/jcp.v67n1110
- Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews, 68(2), 264–355. https://doi.org/https://doi.org/10.1124/pr.115.011478
- Nutt, D., Erritzoe, D., & Carhart-Harris, R. (2020). Psychedelic psychiatry’s brave new world. Cell, 181(1), 24–28. https://doi.org/https://doi.org/10.1016/j.cell.2020.03.020
- Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: A multicriteria decision analysis. The Lancet, 376(9752), 1558–1565. https://doi.org/https://doi.org/10.1016/S0140-6736(10)61462-6
- Oram, M. (2018). The trials of psychedelic therapy: LSD psychotherapy in America. JHU Press.
- Oroc, J. (2011). Psychedelics and extreme sports. Multidisciplinary Association for Psychedelic Studies Bulletin, 21(1), 25–29.
- Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(3), 418–434. https://doi.org/https://doi.org/10.1111/j.1749-6632.1957.tb40738.x
- Park, S., Lavallee, D., & Tod, D. (2013). Athletes’ career transition out of sport: A systematic review. International Review of Sport and Exercise Psychology, 6(1), 22–53. https://doi.org/https://doi.org/10.1080/1750984X.2012.687053
- Polito, V., & Stevenson, R. J. (2019). A systematic study of microdosing psychedelics. PLoS One, 14(2), e0211023. https://doi.org/https://doi.org/10.1371/journal.pone.0211023
- Poucher, Z. A., Tamminen, K. A., Kerr, G., & Cairney, J. (2019). A commentary on mental health research in elite sport. Journal of Applied Sport Psychology, 1–23. https://doi.org/https://doi.org/10.1080/10413200.2019.1668496
- Preller, K. H., Herdener, M., Pokorny, T., Planzer, A., Kraehenmann, R., Stämpfli, P., Liechti, M. E., Seifritz, E., & Vollenweider, F. X. (2017). The fabric of meaning and subjective effects in LSD-Induced States depend on serotonin 2A receptor activation. Current Biology, 27(3), 451–457. https://doi.org/https://doi.org/10.1016/j.cub.2016.12.030
- Preller, K. H., Pokorny, T., Krähenmann, R., Dziobek, I., Stämpfli, P., & Vollenweider, F. X. (2015). The effect of 5-HT2A/1a agonist treatment on social cognition, empathy, and social decision-making. European Psychiatry, 30, 22. https://doi.org/https://doi.org/10.1016/S0924-9338(15)30017-1
- Purcell, R., Gwyther, K., & Rice, S. M. (2019). Mental health in elite athletes: Increased awareness requires an early intervention framework to respond to athlete needs. Sports Medicine – Open, 5(1), 46. https://doi.org/https://doi.org/10.1186/s40798-019-0220-1
- Purcell, R., Rice, S., Butterworth, M., & Clements, M. (2020). Rates and correlates of mental health symptoms in currently competing elite athletes from the Australian national high-performance sports system. Sports Medicine, 50(9), 1683–1694. https://doi.org/https://doi.org/10.1007/s40279-020-01266-z
- Puspanathan, P. (2017). Psychedelic research in Australia: Breaking through the stigma. The Australian and New Zealand Journal of Psychiatry, 51(9), 940–941. https://doi.org/https://doi.org/10.1177/0004867417701580
- Reardon, C. L. (2016). The sports psychiatrist and psychiatric medication. International Review of Psychiatry, 28(6), 606–613. https://doi.org/https://doi.org/10.1080/09540261.2016.1190691
- Reardon, C. L., Hainline, B., Aron, C. M., Baron, D., Baum, A. L., Bindra, A., Budgett, R., Campriani, N., Castaldelli-Maia, J. M., Currie, A., Derevensky, J. L., Glick, I. D., Gorczynski, P., Gouttebarge, V., Grandner, M. A., Han, D. H., McDuff, D., Mountjoy, M., Polat, A., … Engebretsen, L. (2019). Mental health in elite athletes: International Olympic Committee consensus statement (2019). British Journal of Sports Medicine, 53(11), 667–699. https://doi.org/https://doi.org/10.1136/bjsports-2019-100715
- Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., & Rodriguez, C. I. (2020). The work group on biomarkers and novel treatments, a division of the American Psychiatric Association Council of Research. Psychedelics and Psychedelic-Assisted Psychotherapy. American Journal of Psychiatry, 177(5), 399–410. https://doi.org/https://doi.org/10.1176/appi.ajp.2019.19010035
- Rice, S. M., Purcell, R., De Silva, S., Mawren, D., McGorry, P. D., & Parker, A. G. (2016). The mental health of elite athletes: A narrative systematic review. Sports Medicine, 46(9), 1333–1353. https://doi.org/https://doi.org/10.1007/s40279-016-0492-2
- Rice, S. M., Purcell, R., & McGorry, P. D. (2018). Adolescent and young adult male mental health: Transforming system failures into proactive models of engagement. The Journal of Adolescent Health: Official Publication of the Society for Adolescent Medicine, 62(3S), S9–S17. https://doi.org/https://doi.org/10.1016/j.jadohealth.2017.07.024
- Ronkainen, N. J., Kavoura, A., & Ryba, T. V. (2016). A meta-study of athletic identity research in sport psychology: Current status and future directions. International Review of Sport and Exercise Psychology, 9(1), 45–64. https://doi.org/https://doi.org/10.1080/1750984X.2015.1096414
- Rosenbaum, D., Boyle, A. B., Rosenblum, A. M., Ziai, S., Chasen, M. R., & Med, M. P. (2019). Psychedelics for psychological and existential distress in palliative and cancer care. Current Oncology, 26(4), 225–226. https://doi.org/https://doi.org/10.3747/co.26.5009
- Ross, S. (2018). Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International Review of Psychiatry, 30(4), 317–330. https://doi.org/https://doi.org/10.1080/09540261.2018.1482261
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–1180. https://doi.org/https://doi.org/10.1177/0269881116675512
- Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018). Psychiatry & the psychedelic drugs. Past, present & future. Neuropharmacology, 142, 200–218. https://doi.org/https://doi.org/10.1016/j.neuropharm.2017.12.040
- Sampedro, F., de la Fuente Revenga, M., Valle, M., Roberto, N., Domínguez-Clavé, E., Elices, M., Luna, L. E., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., Friedlander, P., Barker, S. A., Álvarez, E., Soler, J., Pascual, J. C., Feilding, A., & Riba, J. (2017). Assessing the psychedelic “after-glow” in ayahuasca users: Post-acute neurometabolic and functional connectivity changes are associated with enhanced mindfulness capacities. The International Journal of Neuropsychopharmacology, 20(9), 698–711. https://doi.org/https://doi.org/10.1093/ijnp/pyx036
- Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015). Acute effects of lysergic acid diethylamide in healthy subjects. Biological Psychiatry, 78(8), 544–553. https://doi.org/https://doi.org/10.1016/j.biopsych.2014.11.015
- Schultes, R. E. (1969). Hallucinogens of plant origin. Science, 163(3864), 245–254. https://doi.org/https://doi.org/10.1126/science.163.3864.245
- Sellers, E. M., & Leiderman, D. B. (2018). Psychedelic drugs as therapeutics: No illusions about the challenges. Clinical Pharmacology and Therapeutics, 103(4), 561–564. https://doi.org/https://doi.org/10.1002/cpt.776
- Shanon, B. (2010). The epistemics of ayahuasca visions. Phenomenology and the Cognitive Sciences, 9(2), 263–280. https://doi.org/https://doi.org/10.1007/s11097-010-9161-3
- Sly, D., Mellalieu, S. D., & Wagstaff, C. R. (2020). It’s psychology Jim, but not as we know it!”: The changing face of applied sport psychology. Sport, Exercise, and Performance Psychology, 9(1), 87–101. https://doi.org/https://doi.org/10.1037/spy0000163
- Stillman, M. A., Glick, I. D., McDuff, D., Reardon, C. L., Hitchcock, M. E., Fitch, V. M., & Hainline, B. (2019). Psychotherapy for mental health symptoms and disorders in elite athletes: A narrative review. British Journal of Sports Medicine, 53(12), 767–771. https://doi.org/https://doi.org/10.1136/bjsports-2019-100654
- Strauss, N., Bright, S. J., & Williams, M. L. (2016). Australia should be initiating a psychedelic research program: What are the barriers? The Australian and New Zealand Journal of Psychiatry, 50(11), 1036–1037. https://doi.org/https://doi.org/10.1177/0004867416670520
- Uphill, M., Sly, D., & Swain, J. (2016). From mental health to mental wealth in athletes: Looking back and moving forward. Frontiers in Psychology, 7, 935. https://doi.org/https://doi.org/10.3389/fpsyg.2016.00935
- van Amsterdam, J., Nutt, D., Phillips, L., & van den Brink, W. (2015). European rating of drug harms. Journal of Psychopharmacology, 29(6), 655–660. https://doi.org/https://doi.org/10.1177/0269881115581980
- Vollenweider, F. X., & Preller, K. H. (2020). Psychedelic drugs: Neurobiology and potential for treatment of psychiatric disorders. Nature Reviews. Neuroscience, 21(11), 611–624. https://doi.org/https://doi.org/10.1038/s41583-020-0367-2
- Wachsmuth, S., Jowett, S., & Harwood, C. G. (2017). Conflict among athletes and their coaches: What is the theory and research so far? International Review of Sport and Exercise Psychology, 10(1), 84–107. https://doi.org/https://doi.org/10.1080/1750984X.2016.1184698
- WADA. (2020). World Anti-Doping Code. Retrieved October 02, 2020 from https://www.wada-ama.org/en/resources/science-medicine/prohibited-list-documents
- Walton, C. C., Baranoff, J., Gilbert, P., & Kirby, J. (2020). Self-compassion, social rank, and psychological distress in athletes of varying competitive levels. Psychology of Sport and Exercise, 50, 101733. https://doi.org/https://doi.org/10.1016/j.psychsport.2020.101733
- Watson, J. C. (2005). College student-athletes’ attitudes toward help-seeking behavior and expectations of counseling services. Journal of College Student Development, 46(4), 442–449. https://doi.org/https://doi.org/10.1353/csd.2005.0044
- Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. Journal of Humanistic Psychology, 57(5), 520–564. https://doi.org/https://doi.org/10.1177/0022167817709585